Efficacy of mipragoside ophthalmic gel in vernal keratoconjunctivitis.

Abstract

To evaluate the efficacy of Mipragoside, a ganglioside derivative, in vernal keratoconjunctivitis we performed a controlled randomised clinical trial involving 24 patients (mean age 10 +/- 3.4 years, range 5-20 years). Patients received either Mipragoside 0.5% aqueous ophthalmic gel or placebo four times a day for 2 weeks after a week of treatment with placebo. Ocular signs and symptoms were evaluated and considered for statistical analysis. Results show that Mipragoside significantly reduces all symptoms, being most effective on itching (p = 0.01; p = 0.0001) and hyperaemia (p = 0.01; p = 0.0006) after 1 and 2 weeks respectively when compared with placebo. Physician judgement of drug efficacy at the end of treatment was significantly in favour of Mipragoside (p = 0.0001) compared with placebo. We conclude that Mipragoside topical treatment improves symptoms of patients with vernal keratoconjunctivitis and we postulate a possible anti-inflammatory activity of this compound.

• Authors: M Centofanti, M Schiavone, A Lambiase, M Taffara, S Giuffrida, S Bonini
• Journal: Eye (London, England) (Eye (Lond)) Vol. 10 ( Pt 4) Pg. 422-4 ( 1996) ISSN: 0950-222X [Print] England
• PMID: 8944090 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Gels
• G(M1) Ganglioside
• mipragoside

Topics

• Administration, Topical
• Adolescent
• Adult
• Child
• Child, Preschool
• Conjunctivitis, Allergic (drug therapy)
• Female
• G(M1) Ganglioside (analogs & derivatives, therapeutic use)
• Gels
• Humans
• Male
• Treatment Outcome